活动性癌症患者孤立性远端深静脉血栓形成的临床病程:一项多中心队列研究
该多中心队列研究纳入13个中心共308例活动性癌症合并客观诊断的孤立性远端深静脉血栓形成(IDDVT)患者,随访355.8患者年期间客观诊断的复发性静脉血栓栓塞症(VTE)发生率为13.2例/100患者年,抗凝治疗期间大出血年发生率为2.0例/100患者年。作者结论认为此类患者VTE复发风险高,需进一步研究最佳抗凝强度与疗程。
要点
- 活动性癌症合并IDDVT患者复发性VTE发生率为13.2例/100患者年。
- 抗凝治疗期间大出血年发生率为2.0例/100患者年。
- 作者认为需进一步研究此类患者的最佳抗凝强度与疗程。
核心结论
- 活动性癌症合并IDDVT患者VTE复发风险高,需进一步研究最佳抗凝强度与疗程。
研究设计与样本
- 多中心队列研究,纳入2011年1月至2014年9月连续的活动性癌症合并客观诊断IDDVT患者,共308例,来自13个中心。
主要发现
- 308例患者平均年龄66.2岁(标准差13.2岁),女性57.1%,实体瘤261例、血液肿瘤47例,转移性癌症148例(48.1%)。
- 除3例外(99.0%)均接受抗凝治疗,其中低分子量肝素288例(93.5%);长期治疗使用维生素K拮抗剂46例(14.9%),其余继续初始肠外抗凝剂,平均治疗时长4.2个月(标准差4.6个月)。
- 总随访355.8患者年(平均13.9个月)期间,共47例复发性客观诊断VTE,发生率为13.2例/100患者年。
- 抗凝治疗期间大出血年发生率为2.0例/100患者年。
临床怎么用
- 原文结论指出活动性癌症合并IDDVT患者VTE复发风险高,并认为需进一步研究最佳抗凝强度与疗程。
局限性
- 原文结论指出需进一步研究以确定此类患者最佳抗凝强度与疗程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Isolated distal deep vein thrombosis (IDDVT) is frequently associated with cancer. No study has specifically evaluated the long-term clinical course of cancer-associated IDDVT. Patients with cancer-associated IDDVT are at very high risk of symptomatic recurrence and death. We observed low rates of major bleeding during anticoagulation. SUMMARY: Background Although isolated distal deep vein thrombosis (IDDVT) is frequently associated with cancer, no study has specifically evaluated the long-term clinical course of IDDVT in this setting. Aim To provide data on the rate of recurrent venous thromboembolism (VTE), major bleeding events and death in IDDVT patients with active cancer. Patients and Methods Consecutive patients with active cancer and an objective IDDVT diagnosis (January 2011 to September 2014) were included from our files. We collected information on baseline characteristics, IDDVT location and extension, VTE risk factors, and type and duration of anticoagulant treatment. Results A total of 308 patients (mean age 66.2 [standard deviation (SD), 13.2 years]; 57.1% female) with symptomatic IDDVT and a solid (n = 261) or hematologic (n = 47) cancer were included at 13 centers. Cancer was metastatic in 148 (48.1%) patients. All but three (99.0%) patients received anticoagulant therapy, which consisted of low-molecular-weight heparin in 288 (93.5%) patients. Vitamin K antagonists were used for the long-term treatment in 46 (14.9%) patients, whereas all others continued the initial parenteral agent for a mean treatment duration of 4.2 months (SD, 4.6 months). During a total follow-up of 355.8 patient-years (mean, 13.9 months), there were 47 recurrent objectively diagnosed VTEs for an incidence rate of 13.2 events per 100 patient-years. During anticoagulant treatment, the annual incidence of major bleeding was 2.0 per 100 patient-years. Conclusions Cancer patients with IDDVT have a high risk of VTE recurrence. Additional studies are warranted to investigate the optimal intensity and duration of anticoagulant treatment for these patients.
引用
- Dentali F, Pegoraro S, Barco S, et al. Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study. J Thromb Haemost. 2017. PMID: 28639418. doi:10.1111/jth.13761
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。